RecruitingPhase 3NCT05354141

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Moderate-to-Severe ARDS: A Phase III Clinical Trial

Sponsor

Direct Biologics, LLC

Enrollment

970 participants

Start Date

Jul 1, 2022

Study Type

INTERVENTIONAL

Conditions

ARDS Acute Respiratory Distress Syndrome

Summary

To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria7

Men and women aged 18-75 years of age
Presence of the following criteria for moderate to severe ARDS as defined by the Berlin Criteria within 24 hours of the first infustion:
Onset within 7 days of known clinical insult or requiring increasing respiratory rate, increasing oxygen flows, or increased work of breathing, and
Bilateral lung opacities not fully explained by pleural effusions, atelectasis, or nodules, and
PaO2/FiO2 (P/F ratio) ≤ 200 mm Hg, and
Invasive or noninvasive ventilation with a minimum PEEP 5 cm H2O or minimum of continuous positive airway pressure (CPAP) 5 cm H2O, or High Flow Nasal Oxygen at ≥ 30 L/min, and
Respiratory failure not fully explained by cardiac failure or fluid overload.

Exclusion Criteria14

Lack of signed and dated informed consent form (either by the individual or by the individual's healthcare proxy).
Stated unwillingness to comply with all study procedures and availability for the duration of the study
Vulnerable populations such as pregnant patients, children, individuals with severe physical or mental disabilities who cannot provide meaningful consent.
Active malignancy requiring treatment within the last two years, with the exception of non-melanoma skin cancers.
Major physical trauma in the last 2 days, including motor vehicle accidents, assaults, mechanical falls with sequelae of significant bleeding or craniofacial bruising, and surgeries, such that not one or more injury may be undiagnosed at time of screening.
Duration of mechanical ventilation exceeds 3 days or 72 hours from diagnosis of ARDS.
ALT or AST \> 8 x Upper Limit of Normal (ULN).
Documented history of cirrhosis.
DNR order, as in electing not to receive chest compressions, cardiac defibrillation, cardiac drugs, or intubation.
Moribund-expected survival \< 24 hours.
Severe metabolic disturbances at randomization (e.g., ketoacidosis, pH \< 7.2)
Patient currently connected to Extracorporeal Membrane Oxygenation at initiation of screening.
If the candidate, either a male or female of reproductive potential, is unwilling to two methods of highly effective birth control contraception such as condoms with oral contraceptive pill or choose to remain abstinent if already practicing abstinence during the screening period. The required duration of usage of double method OR maintenance of abstinence must include the time from the beginning of the screening period until Day 61, day of withdrawal or early termination
Use of investigational COVID-19 agents or any other investigational agents within 30 days prior to the first dose.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALExoFlo

Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles

OTHERIntravenous normal saline

Placebo